Publication | Closed Access

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

Metabolic SyndromeDiabetes ManagementDiabetesPharmacologyType 2PharmacotherapyNovel Dual GipDiabetes MellitusMedicine